Article info

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

Authors

  1. Correspondence to Dr Kevin L Winthrop, Division of Infectious Diseases, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA; Winthrop{at}ohsu.edu
View Full Text

Citation

Winthrop KL, Novosad SA, Baddley JW, et al
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

Publication history

  • Received April 24, 2015
  • Revised July 31, 2015
  • Accepted August 28, 2015
  • First published September 22, 2015.
Online issue publication 
November 10, 2015

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.